A multicentre, prospective, randomised study of the value of a single dose of intravesical Mitomycin-C in preventing the development of bladder tumours following nephroureterectomy for transitional cell carcinoma (TCC) of the upper urinary tract
ISRCTN | ISRCTN36343644 |
---|---|
DOI | https://doi.org/10.1186/ISRCTN36343644 |
Secondary identifying numbers | 0062/WASH/2000 |
- Submission date
- 29/07/2005
- Registration date
- 02/09/2005
- Last edited
- 17/10/2018
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Plain English summary of protocol
Contact information
Mr Tim O'Brien
Scientific
Scientific
Department of Urology
1st floor Thomas Guy House
Guy's Hospital
St Thomas Street
London
SE1 9RT
United Kingdom
Phone | +44 (0)207 1886796 |
---|---|
tim.obrien@gstt.nhs.uk |
Study information
Study design | Randomised controlled trial |
---|---|
Primary study design | Interventional |
Secondary study design | Randomised controlled trial |
Study setting(s) | Hospital |
Study type | Prevention |
Participant information sheet | Not available in web format, please use the contact details below to request a patient information sheet |
Scientific title | A multicentre, prospective, randomised study of the value of a single dose of intravesical Mitomycin-C in preventing the development of bladder tumours following nephroureterectomy for transitional cell carcinoma (TCC) of the upper urinary tract |
Study acronym | ODMIT-C |
Study objectives | The hypothesis is that a single dose of intravesical Mitomycin-C prevents tumour recurrence in the bladder following nephroureterectomy for a transitional cell carcinoma of the upper urinary tract. |
Ethics approval(s) | Not provided at time of registration |
Health condition(s) or problem(s) studied | Upper tract TCC bladder |
Intervention | Intravesical instillation of Mitomycin-C post operatively versus no Mitomycin-C |
Intervention type | Drug |
Pharmaceutical study type(s) | |
Phase | Not Applicable |
Drug / device / biological / vaccine name(s) | Mitomycin-C |
Primary outcome measure | Incidence of tumour recurrence at 1 year post nephroureterectomy |
Secondary outcome measures | To study the post surgical survival of these patients over five years. |
Overall study start date | 20/07/2000 |
Completion date | 01/12/2007 |
Eligibility
Participant type(s) | Patient |
---|---|
Age group | Adult |
Sex | Both |
Target number of participants | 268 |
Key inclusion criteria | 1. A new clinical diagnosis of a transitional cell tumour of the upper urinary tract above the intramural ureter 2. A negative cystoscopy for TCC bladder within one month of the nephroureterectomy 3. A nephroureterectomy that is planned to be performed in such a way that there is early distal ligation of the ureter prior to the mobilisation of the tumour. The intramural portion of the ureter may be resected prior to the open part of the operation, taken at the open operation with a cuff of bladder or everted at the end of the operation and resected endoscopically according to surgical preference. 4. Have a life expectancy of at least one year 5. Informed consent to participate (written and witnessed) |
Key exclusion criteria | 1. The histology of the upper tract tumour does not confirm a transitional cell carcinoma 2. Stage N1 or M1 3. Had additional systemic chemotherapy or additional intravesical Mitomycin-C at follow up cystoscopies 4. Existing or previous transitional cell carcinoma of bladder 5. Children, pregnant women excluded 6. Life expectancy less than one year 7. Known sensitivity to Mitomycin-C |
Date of first enrolment | 20/07/2000 |
Date of final enrolment | 01/12/2007 |
Locations
Countries of recruitment
- England
- United Kingdom
Study participating centre
Guy's Hospital
London
SE1 9RT
United Kingdom
SE1 9RT
United Kingdom
Sponsor information
Sussex NHS Research Consortium (UK)
Government
Government
Research Department
Worthing Hospital
Lyndhurst Road
Worthing
BN11 2DH
United Kingdom
Phone | +44 (0)1903 285224 |
---|---|
john.sitzia@wash.nhs.uk |
Funders
Funder type
Charity
Guy's and St. Thomas' Charity (UK)
Private sector organisation / Trusts, charities, foundations (both public and private)
Private sector organisation / Trusts, charities, foundations (both public and private)
- Alternative name(s)
- Guy's and St Thomas' Charity, Guy's and St Thomas' Foundation, GSTTFoundation
- Location
- United Kingdom
Results and Publications
Intention to publish date | |
---|---|
Individual participant data (IPD) Intention to share | No |
IPD sharing plan summary | Not provided at time of registration |
Publication and dissemination plan | Not provided at time of registration |
IPD sharing plan |
Study outputs
Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
---|---|---|---|---|---|
Plain English results | No | Yes | |||
Results article | results | 01/10/2011 | Yes | No |
Editorial Notes
17/10/2018: Cancer Research UK lay results summary link added to Results (plain English)